Zobrazeno 1 - 10
of 35
pro vyhledávání: '"Mathias Muth"'
Autor:
Peyman Hadji, Oliver Stoetzer, Thomas Decker, Christian M. Kurbacher, Frederik Marmé, Andreas Schneeweiss, Christoph Mundhenke, Andrea Distelrath, Peter A. Fasching, Michael P. Lux, Diana Lüftner, Wolfgang Janni, Mathias Muth, Julia Kreuzeder, Claudia Quiering, Eva-Marie Grischke, Hans Tesch
Publikováno v:
Journal of Bone Oncology, Vol 14, Iss , Pp - (2019)
Background: Breast cancer and its treatments are associated with a detrimental effect on bone health. Here we report the results of an exploratory analysis assessing changes in levels of biomarkers of bone metabolism in patients enrolled in the phase
Externí odkaz:
https://doaj.org/article/c2654a29bfbd4af0b90b6c2e4cd0ef03
Autor:
Claudia Quiering, Frederik Marmé, Christian M. Kurbacher, Florin-Andrei Taran, Christoph Mundhenke, J Kreuzeder, Thomas Decker, Wolfgang Janni, Oliver J. Stoetzer, Hans Tesch, Andrea Distelrath, Michael P. Lux, Diana Lüftner, Andreas Schneeweiss, Mathias Muth, Peter A. Fasching, Peyman Hadji
Publikováno v:
International Journal of Cancer
In BOLERO‐2, adding everolimus to exemestane resulted in a twofold increase in median progression‐free survival (PFS) vs exemestane in postmenopausal women with hormone receptor‐positive (HR+), human epidermal growth factor receptor 2‐negativ
Autor:
Klaus Mohr, Evi Kostenis, Mathias Muth, Ramona Schrage, Jessica Kloeckner, Janine Holze, Anna De Min, Carlo Matera, Ulrike Holzgrabe, Terry P. Kenakin, Clelia Dallanoce, Andreas Bock, Marco De Amici, Christian Traenkle
Publikováno v:
Molecular Pharmacology. 91:348-356
Protean agonists are of great pharmacological interest as their behavior may change in magnitude and direction depending on the constitutive activity of a receptor. Yet, this intriguing phenomenon has been poorly described and understood, due to the
Autor:
Oliver Stoetzer, Christoph Mundhenke, Eva-Marie Grischke, Peyman Hadji, Wolfgang Janni, Hans Tesch, Frederik Marmé, Christian M. Kurbacher, Thomas Decker, Andreas Schneeweiss, Diana Lüftner, Mathias Muth, J Kreuzeder, Peter A. Fasching, Andrea Distelrath, Michael P. Lux, Claudia Quiering
Publikováno v:
Journal of Bone Oncology, Vol 14, Iss, Pp-(2019)
Journal of Bone Oncology
Journal of Bone Oncology
Background: Breast cancer and its treatments are associated with a detrimental effect on bone health. Here we report the results of an exploratory analysis assessing changes in levels of biomarkers of bone metabolism in patients enrolled in the phase
Autor:
Hans Tesch, Nadia Harbeck, J Kreuzeder, Sherko Kuemmel, Christoph Mundhenke, Christian Jackisch, Andreas Schneeweiss, Mathias Muth, Christian M. Kurbacher, Oliver Tomé, Christoph Uleer, Eva-Maria Grischke, Bettina Mueller, Florian Schütz, Diana Lüftner, Peter A. Fasching, Wilhelm Bloch, Thomas Decker, Pauline Wimberger, F Förster
Publikováno v:
Cancer Research. 75:P5-19
Introduction BRAWO is a German non-interventional study of 3000 patients (pts) with advanced or metastatic, hormone-receptor-positive, HER2-negative breast cancer treated with everolimus (EVE) and exemestane (EXE). We report results of the 2nd prepla
Autor:
Diana Lüftner, Wolfgang Janni, Peyman Hadji, Hans Tesch, Micheal P Lux, J Kreuzeder, Oliver Stoetzer, Christoph Mundhenke, Peter A. Fasching, Romy Neumeister, Thomas Decker, Frederik Marmé, Christian M. Kurbacher, Andreas Schneeweiss, Mathias Muth, Claudia Weiss, Andrea Distelrath, Eva-Maria Grischke
Publikováno v:
Cancer Research. 75:P3-06
Introduction: The BOLERO-2 study showed significant doubling of PFS benefit with the addition of EVE to EXE in postmenopausal women with hormone receptor–positive advanced breast cancer progressing after non-steroidal aromatase inhibitor (NSAI) the
Autor:
Peter H. Kann, Monika Baier, Annette Kauka, Mathias Muth, Peyman Hadji, M. Ziller, Katrin Birkholz
Publikováno v:
Breast Cancer Research and Treatment. 144:343-351
Endocrine therapy (ET) is a key treatment modality in hormone receptor positive (HR+) early breast cancer (BC) patients. Although the anticancer activity of adjuvant ET + zoledronic acid (ZOL) has been investigated, the potential effects of ET ± ZOL
Autor:
Mathias Muth, Peyman Hadji, M. Ziller, Martina Bauer, Monika Baier, Katrin Birkholz, Anette Kauka
Publikováno v:
Osteoporosis International. 25:1369-1378
The effects of bisphosphonates on altered bone turnover marker (BTM) levels associated with adjuvant endocrine or chemotherapy in early breast cancer have not been systematically investigated. In ProBONE II, zoledronic acid decreased these elevated B
Autor:
Sven Hanson, Fritz Werner Schaefer, Mathias Muth, Marion T. Weigel, Antonia Wenners, Maret Bauer, Nicolai Maass, Dirk Bauerschlag, Ibrahim Alkatout, Christian Schem, Walter Jonat, Christoph Mundhenke, Monika Baier, Katharina Tiemann
Publikováno v:
Oncology. 87:300-310
Background: Imatinib is a tyrosine kinase inhibitor of BCR-ABL, ABL, PDGFR-α and -β, KIT, and DDR. In solid tumors, it inhibits proliferation and invasiveness and facilitates higher intratumoral cytotoxic drug concentrations. Vinorelbine has good t
Autor:
Thomas Decker, Peter A. Fasching, Wolfgang Janni, Hans Tesch, Erik Belleville, D Lueftner, J Kreuzeder, Michael P. Lux, Andreas Schneeweiss, Mathias Muth, D. Wallwiener, P. Hadji
Publikováno v:
Cancer Research. 73:OT2-6
BACKGROUND The double blind, placebo-controlled BOLERO-2 trial demonstrated a significant doubling of progression free survival (PFS) with EVE and EXE compared to EXE alone for postmenopausal women with hormone-receptor positive (HR+), human epiderma